10x Genomics is trading 4.5% down at $45.32, with pre-earnings positioning and valuation concerns the most likely immediate pressures ahead of its Q2 2026 results after market close.
- No confirmed company-specific announcement or earnings result was found during the August 6, 2026 session.
- The decline comes despite biotech strength, with XBI up 2.09%, so sector weakness does not explain the move.
- Broader indexes are mixed and offer no strong same-direction catalyst.